Eli Lilly Canada Inc., in collaboration with Health Canada, has informed healthcare professionals that sales of Permax will cease in Canada as of August 30, 2007.
Subsequent to new post-market safety information coming from two papers published in the January 4, 2007 issue of the New England Journal of Medicine (NEJM) that provided further evidence consistent with previous reports of valvulopathy cases in patients taking pergolide,1 2 Health Canada considers that there is insufficient evidence to support the continued safe use of Permax under the current recommendations outlined in the Product Monograph.
Source and detailed report: http://www.docguide.com/news/content.nsf/news/852571020057CCF685257339005C676C?OpenDocument&id=48DDE4A73E09A969852568880078C249&c=Parkinson&count=10
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment